It looks like some wishes do come true. Inhibitex
What makes Bristol's offer so startling is that Inhibitex's headline drug, INX-189, is only through phase 1 clinical trials. Granted, it posted some exciting efficacy data, but it is behind Pharmasset's PSI-7977 and still has a long, long way to go before FDA approval. Obviously, Pharmasset was a much larger company with a more extensive pipeline, so the total dollar value paid by Gilead was significantly higher, but what both of these deals show is how excited the major drug companies are about these next-gen hep C treatments.
The biggest loser here is likely Vertex Pharmaceuticals
If you missed out on Inhibitex's instant double, don't worry. Motley Fool co-founder David Gardner has found a small health-care stock on the cusp of blockbuster growth and is offering to share its name with you for free in our special report "Discover the Next Rule-Breaking Multibagger." This must-read special free report is available for a limited time, so download it right now and don't miss your opportunity for truly market-beating returns.
David Williamson holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.